Last reviewed · How we verify
Peg-IFN + LD RBV for 16 weeks
Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress viral replication in hepatitis C infection.
Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress viral replication in hepatitis C infection. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | Peg-IFN + LD RBV for 16 weeks |
|---|---|
| Also known as | Pegasys plus Copegus |
| Sponsor | National Taiwan University Hospital |
| Drug class | Antiviral combination therapy |
| Target | Interferon alpha receptor; HCV RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Pegylated interferon alpha (Peg-IFN) is a long-acting form of interferon that activates innate and adaptive immune responses against hepatitis C virus (HCV). Ribavirin (RBV) is a nucleoside analog that inhibits viral RNA synthesis and enhances interferon-induced immune responses. The combination therapy works synergistically to reduce HCV viral load and achieve sustained virologic response.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Anemia
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Headache
- Nausea
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |